Javascript must be enabled to continue!
Renal Nephron Segment‐Specific Gene Expression using Adeno‐Associated Viral (AAV) Vectors
View through CrossRef
AAV vectors provide sustained long‐term gene expression with minimal immunological consequences. Systemic administration of AAV9 vector transduces efficiently various organs, such as the liver, heart, lung and skeletal muscle but provides very low transduction in the kidney. We have reported that the administration of AAV9 vector by retrograde ureteral infusion provided efficient gene transfer to renal cells including proximal and distal tubule cells, and podocytes with minimum off‐target gene expression. In studies on the genetics of renal tubule function, it is important to restrict the expression of the transgene to the desired cell type within the kidney, so that the physiological parameters measured will represent the function of the transgene expressed in that specific renal cell type. We hypothesized that use of nephron segment‐specific promoters sodium‐glucose cotransporter‐2 (SGLT2), Na
+
‐K
+
‐Cl
−
cotransporter‐2 (NKCC2), E‐cadherin (ECAD), and kidney‐specific cadherin (KSPC) promoters will provide preferential gene expression in the proximal tubule, thick ascending limb of Henle (TALH), distal convoluted tubule, collecting duct, and entire nephron, respectively. We have constructed, and validated in appropriate cell lines, AAV vector encoding EGFP gene under the control of nephron segment‐specific promoters SGLT2, NKCC2, ECAD, or KSPC. AAV9 vector with SGLT2 promoter driving the expression of EGFP provided robust expression in mouse primary renal proximal tubule cells but not renal collecting duct cells. KSPC promoter provided AAV9‐mediated expression in primary mouse renal proximal tubule as well as renal collecting duct cells. NKCC2 promoter provided weak expression in primary mouse renal proximal tubule and collecting duct cells. Specificity and distribution of gene expression in the mouse kidney from each promoter was determined by immunofluorescence staining using antibody against the marker proteins for proximal tubule, TALH, distal convoluted tubule, and collecting duct cells. Preliminary results, using SGLT2, a proximal tubule‐specific promoter, showed expression of EGFP only in proximal tubules of the mouse kidney. These results demonstrate that AAV9 vectors carrying nephron segment‐specific promoters can provide expression in their respective segment of the nephron.
Title: Renal Nephron Segment‐Specific Gene Expression using Adeno‐Associated Viral (AAV) Vectors
Description:
AAV vectors provide sustained long‐term gene expression with minimal immunological consequences.
Systemic administration of AAV9 vector transduces efficiently various organs, such as the liver, heart, lung and skeletal muscle but provides very low transduction in the kidney.
We have reported that the administration of AAV9 vector by retrograde ureteral infusion provided efficient gene transfer to renal cells including proximal and distal tubule cells, and podocytes with minimum off‐target gene expression.
In studies on the genetics of renal tubule function, it is important to restrict the expression of the transgene to the desired cell type within the kidney, so that the physiological parameters measured will represent the function of the transgene expressed in that specific renal cell type.
We hypothesized that use of nephron segment‐specific promoters sodium‐glucose cotransporter‐2 (SGLT2), Na
+
‐K
+
‐Cl
−
cotransporter‐2 (NKCC2), E‐cadherin (ECAD), and kidney‐specific cadherin (KSPC) promoters will provide preferential gene expression in the proximal tubule, thick ascending limb of Henle (TALH), distal convoluted tubule, collecting duct, and entire nephron, respectively.
We have constructed, and validated in appropriate cell lines, AAV vector encoding EGFP gene under the control of nephron segment‐specific promoters SGLT2, NKCC2, ECAD, or KSPC.
AAV9 vector with SGLT2 promoter driving the expression of EGFP provided robust expression in mouse primary renal proximal tubule cells but not renal collecting duct cells.
KSPC promoter provided AAV9‐mediated expression in primary mouse renal proximal tubule as well as renal collecting duct cells.
NKCC2 promoter provided weak expression in primary mouse renal proximal tubule and collecting duct cells.
Specificity and distribution of gene expression in the mouse kidney from each promoter was determined by immunofluorescence staining using antibody against the marker proteins for proximal tubule, TALH, distal convoluted tubule, and collecting duct cells.
Preliminary results, using SGLT2, a proximal tubule‐specific promoter, showed expression of EGFP only in proximal tubules of the mouse kidney.
These results demonstrate that AAV9 vectors carrying nephron segment‐specific promoters can provide expression in their respective segment of the nephron.
Related Results
The Use of Adeno-associated virus (AAV) in Vaccine Development
The Use of Adeno-associated virus (AAV) in Vaccine Development
Adeno-associated virus (AAV) is a very tiny (20-26 nm) icosahedral and non-enveloped virus, and it belongs to the Parvoviridae family. AAV vectors are the most widely used ...
The plasma proteome reveals distinct signaling pathways associated with PR3-ANCA positive and MPO-ANCA positive vasculitis
The plasma proteome reveals distinct signaling pathways associated with PR3-ANCA positive and MPO-ANCA positive vasculitis
ObjectiveDespite recent advances, the pathophysiological mechanisms underlying anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) remain incompletely underst...
Improved Genome Packaging Efficiency of AAV Vectors Using Rep Hybrids
Improved Genome Packaging Efficiency of AAV Vectors Using Rep Hybrids
Abstract
Recombinant Adeno-associated viruses (rAAVs) are one of the most commonly used vectors for a variety of gene therapy applications. In th...
Post‐translational modifications in capsid proteins of recombinant adeno‐associated virus (
AAV
) 1‐rh10 serotypes
Post‐translational modifications in capsid proteins of recombinant adeno‐associated virus (
AAV
) 1‐rh10 serotypes
Post‐translational modifications in viral capsids are known to fine‐tune and regulate several aspects of the infective life cycle of several viruses in the host. Recombinant viruse...
Adeno‐associated Viral Vectors in Gene Therapy
Adeno‐associated Viral Vectors in Gene Therapy
Abstract
Recombinant vectors based on a nonpathogenic human parvovirus, the
adeno‐associated virus
(A...
Targeted Modifications in Adeno-Associated Virus Serotype (AAV)- 8 Capsid Improves Its Hepatic Gene Transfer Efficiency in Vivo
Targeted Modifications in Adeno-Associated Virus Serotype (AAV)- 8 Capsid Improves Its Hepatic Gene Transfer Efficiency in Vivo
Abstract
Abstract 2045
Recombinant adeno-associated virus vectors based on serotype (AAV)-8 have shown significant promise for liver directed gene the...
Prophylaxis CTLA4-ig reduces anti-AAV neutralizing antibodies in AAV gene therapy for hemophilia
Prophylaxis CTLA4-ig reduces anti-AAV neutralizing antibodies in AAV gene therapy for hemophilia
Abstract
Objective: This study aimed to investigate the inhibitory effect of CTLA4-Ig on anti-AAV neutralizing antibody ...
Changing incidence and serotype trends in ANCA-associated vasculitis: a 30-year population-based study in Norfolk, UK
Changing incidence and serotype trends in ANCA-associated vasculitis: a 30-year population-based study in Norfolk, UK
Abstract
Objectives
The ANCA associated vasculitides (AAV) are rare diseases with poor outcomes if untreated. Over a 30-y...

